Amidst the ashes of the dot coms, one ember of the computing economy remains red hot: bioinformatics. The potential of the field-which brings the combined power of computers and biological data to bear on problems ranging from agriculture to drug discovery-is so great that otherwise technology-wary investors are continuing to back new startups, and deals in the area are taking off. One catch: a deficit of qualified people with the right blend of skills in computer science and molecular biology to staff the booming business.
“By almost any measure [bioinformatics is] growing,” says David Searls, head of bioinformatics at GlaxoSmithKline. “You can look at number of positions; you can look at number of companies; you can look at academia.” Indeed, deals between bioinformatics firms and other biotech or drug companies are on the rise, according to a recent report from Cambridge Healthtech Institute; 79 were inked in the first quarter of this year, compared with 55 for the same period in 2000. Leading the way was the sale of Kirkland, WA, bioinformatics firm Rosetta Inpharmatics to drug giant Merck for $620 million in May.
As investment has dried up completely in many technology sectors, the venture capital market has held for bioinformatics firms. “It’s definitely decoupled from the downturn in technology funding,” says Emmett Power, CEO of London-based Silico Research. Several bioinformatics companies have closed on funding in 2001: life-sciences peer-to-peer computing company Entropia received $23 million in second-round funding in January; Spotfire, a data analysis software maker, announced $15 million in additional funding in February; and life-sciences computing infrastructure provider Viaken Systems announced $13 million in its second round in June.
Staffing problems, however, threaten to put the brakes on the surge in bioinformatics activity. The field is so hot, says Nat Goodman, senior vice president of Cambridge, MA-based bioinformatics consultancy 3rd Millennium, that companies and universities alike can find only about half the number of people they need.
The new version of GPT-3 is much better behaved (and should be less toxic)
OpenAI has trained its flagship language model to follow instructions, making it spit out less unwanted text—but there's still a way to go.
A horrifying new AI app swaps women into porn videos with a click
Deepfake researchers have long feared the day this would arrive.
We can’t afford to stop solar geoengineering research
It is the wrong time to take this strategy for combating climate change off the table.
Meet Altos Labs, Silicon Valley’s latest wild bet on living forever
Funders of a deep-pocketed new "rejuvenation" startup are said to include Jeff Bezos and Yuri Milner.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.